Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,440 stopped studies mapped to Adenocarcinoma and descendants · 92% state a reason
Over the 1,440 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02147301 | TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve | N/A | terminated | May 26, 2014 | University of California, San Francisco | Risk to benefit ratio is not acceptable | Other (stated, no rule matched) |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | Phase 1 / Phase 2 | withdrawn | Jun 9, 2015 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT02946138 | Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of… | Phase 2 | withdrawn | Oct 27, 2016 | Shanghai Proton and Heavy Ion Center | enrollment was too slow | Enrollment / accrual |
| NCT01737151 | Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk… | N/A | terminated | Nov 29, 2012 | Virginia Commonwealth University | Slow accrual | Enrollment / accrual |
| NCT01817205 | Combined Chemoembolization and Systemic Hyperthermia for Unresectable Hepatocellular… | N/A | terminated | Mar 25, 2013 | Chinese University of Hong Kong | poor case accrual | Enrollment / accrual |
| NCT00323076 | [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal… | Phase 1 / Phase 2 | terminated | May 9, 2006 | AHS Cancer Control Alberta | Retirement of former Qualified Investigator and lack of resources to complete study. | Investigator |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic… | Early Phase 1 | terminated | Mar 29, 2018 | PH Research, S.L. | Stopped Enrollment | Enrollment / accrual |
| NCT03523299 | Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer | N/A | withdrawn | May 14, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Principal investigator wishes to revisit design and start a new study | Investigator |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer… | Phase 2 | terminated | Nov 10, 2006 | National Cancer Institute (NCI) | The study was terminated after all enrolled participants progressed. | Enrollment / accrual |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer… | Phase 2 | terminated | May 24, 2007 | National Cancer Institute (NCI) | Due to slow accrual | Enrollment / accrual |
| NCT02233595 | Evaluation of Rectal Cancer Treatment Response Using PET/MRI(Rectal PET/MRI) | — | terminated | Sep 8, 2014 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT01806740 | DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients…(DCE-MRI) | Phase 4 | terminated | Mar 7, 2013 | Guerbet | The planned number of enrolled patients was not reached. | Enrollment / accrual |
| NCT03777579 | A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in… | Phase 3 | suspended | Dec 17, 2018 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | trial handovered to another sponser. | Other (stated, no rule matched) |
| NCT01465464 | Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With…(ORIENTAL) | Phase 3 | terminated | Nov 4, 2011 | Taiho Pharmaceutical Co., Ltd. | not stated | Not stated |
| NCT02707328 | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With… | Phase 1 | terminated | Mar 14, 2016 | The Cooper Health System | Closed after being on administrative hold | Other (stated, no rule matched) |
| NCT01739439 | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance… | Phase 1 | terminated | Dec 3, 2012 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02404363 | Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic…(PANCREADOGREL) | Phase 3 | terminated | Mar 31, 2015 | Assistance Publique - Hôpitaux de Paris | recruitment problem | Enrollment / accrual |
| NCT00262821 | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With… | Phase 3 | terminated | Dec 7, 2005 | National Cancer Institute (NCI) | Study drug no longer available resulting in lack of study drug for participants. | Other (stated, no rule matched) |
| NCT01391130 | A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Jul 11, 2011 | Eli Lilly and Company | Study Terminated due to Insufficient Efficacy | Efficacy / futility |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 2, 2016 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or… | Phase 1 / Phase 2 | withdrawn | Dec 19, 2018 | Alan Katz | CCX872-B will not be available in sufficient quantity to conduct the study. | Other (stated, no rule matched) |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Phase 2 | terminated | Oct 24, 2017 | Effector Therapeutics | The study was terminated due to change in focus of the development program | Other (stated, no rule matched) |
| NCT02124369 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE) | Phase 2 | terminated | Apr 28, 2014 | CCTU- Cancer Theme | Poor accrual | Enrollment / accrual |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | Phase 1 / Phase 2 | withdrawn | Apr 13, 2017 | William Grosh, MD | funding was withdrawn | Funding |
| NCT00538772 | An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell… | — | withdrawn | Oct 3, 2007 | Kim Chi | not stated | Not stated |
| NCT01138553 | Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer | Early Phase 1 | terminated | Jun 7, 2010 | University of California, San Diego | Inadequate subject accrual | Enrollment / accrual |
| NCT02428335 | Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib | — | withdrawn | Apr 28, 2015 | AHS Cancer Control Alberta | Insufficient financial resources to conduct research and complete trial. | Funding |
| NCT03528057 | Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy | N/A | withdrawn | May 17, 2018 | Northwestern University | Difficulty recruiting participants. | Enrollment / accrual |
| NCT02005614 | A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI… | N/A | terminated | Dec 9, 2013 | Yale University | Unable to recruit patients. | Enrollment / accrual |
| NCT03349255 | Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma | Phase 1 | terminated | Nov 21, 2017 | Aeon Therapeutics (Shanghai) Co., Ltd. | Will study new T-cell construct for the same indication | Other (stated, no rule matched) |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | Phase 2 | withdrawn | Feb 11, 2019 | University of Oklahoma | Study was not initiated. | Other (stated, no rule matched) |
| NCT02736578 | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients… | Phase 2 | terminated | Apr 13, 2016 | Eben Rosenthal | Logistics | Other (stated, no rule matched) |
| NCT03185182 | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma(RCCSCAN) | Phase 2 | terminated | Jun 14, 2017 | Region Skane | Due to "early stopping rule" as defined in the study protocol | Other (stated, no rule matched) |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin +… | Phase 1 / Phase 2 | withdrawn | Oct 5, 2018 | Hitendra Patel | FDA indicated the same study could not be conducted under multiple INDs | Other (stated, no rule matched) |
| NCT01195649 | Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or… | — | terminated | Sep 6, 2010 | Bayer | not stated | Not stated |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin…(LD-FOX4/HCC) | Phase 2 / Phase 3 | withdrawn | Aug 19, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT02534337 | Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for… | Phase 2 / Phase 3 | withdrawn | Aug 27, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy… | Phase 2 / Phase 3 | withdrawn | Oct 22, 2015 | Guangxi Medical University | not stated | Not stated |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for… | Phase 2 / Phase 3 | withdrawn | Oct 23, 2015 | Guangxi Medical University | It doesn't meet the requirements of randomized trials | Other (stated, no rule matched) |
| NCT03919383 | Phase II of Lenvatinib Plus Toripalimab for Advanced HCC | Phase 2 | withdrawn | Apr 18, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03432676 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | Phase 2 | withdrawn | Feb 14, 2018 | M.D. Anderson Cancer Center | Incyte (supporter of the study) is no longer going to support the study. | Other (stated, no rule matched) |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and… | Phase 1 / Phase 2 | withdrawn | Apr 9, 2019 | Medical College of Wisconsin | Request to close per funding sponsor. Site not moving forward with trial. | Funding |
| NCT03300401 | Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing… | N/A | withdrawn | Oct 3, 2017 | University of Southern California | Accrual issue | Enrollment / accrual |
| NCT01290523 | Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With… | N/A | terminated | Feb 7, 2011 | University of California, San Francisco | Off study clinical use of Y90 glass microspheres (TheraSphere) | Other (stated, no rule matched) |
| NCT02817607 | Study to Assess Breast Sensation Before and After Breast Cancer Treatment | N/A | withdrawn | Jun 29, 2016 | Duke University | not stated | Not stated |
| NCT03775707 | Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria | Phase 2 | withdrawn | Dec 14, 2018 | Shi Ming | Protocol modification | Other (stated, no rule matched) |
| NCT03780634 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | Phase 2 | withdrawn | Dec 19, 2018 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT03803254 | HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | Phase 2 | withdrawn | Jan 14, 2019 | Sun Yat-sen University | No participants enrolled | Enrollment / accrual |
| NCT00727532 | Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | N/A | terminated | Aug 4, 2008 | Northwestern University | Low Accrual | Enrollment / accrual |
| NCT03744247 | Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | Phase 3 | withdrawn | Nov 16, 2018 | Sun Yat-sen University | No paritcipants enrolled | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Sep 10, 2019source: clinicaltrials